CTLA4 and neoplasm: Several studies have focused on tumour-localized rather than systemic administration of anti-CTLA-4 to specifically expand lymphocytes at the tumour site, with some success [55], [60] and this strategy could be applied to the vaccine regimen reported here to further enhance efficacy.